Second-Line Treatment of HER2+ mBC and Recent Data Updates

Maryam Lustberg, MD, MPH introduces the standard of care regimens for the second-line treatment of HER2+ metastatic breast cancer, followed by a discussion of recent data on the ADC trastuzumab deruxtecan (T-DXd).

Related Content:

Updates in HER2+ Early and Metastatic Breast CancerBreast CancerOncLive Peer Exchange®

Adjuvant CDK4/6 Inhibition Gains Further Ground in HR+/HER2– Early Breast Cancer With Ribociclib Approval

5-Year Phase 2 Data Show 0% Recurrence Rate After Surgery Omission in Select Patients With Invasive Breast Cancer

OncLive’s FDA Approval Report: The Regulatory Rundown for April 2025